---
annotation-target: hs9-6-e757.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-30T01:50:16.518Z","text":"帕比司他（panobinostat）是强有力的脱乙酰酶抑制剂，脱乙酰酶是多发性骨髓瘤畸变的目标..","updated":"2022-08-30T01:50:16.518Z","document":{"title":"hs9-6-e757.pdf","link":[{"href":"urn:x-pdf:b92cff942e6c35408e1de9da383cc941"},{"href":"vault:/hematology-theroy/papers/20220808/hs9-6-e757.pdf"}],"documentFingerprint":"b92cff942e6c35408e1de9da383cc941"},"uri":"vault:/hematology-theroy/papers/20220808/hs9-6-e757.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/hs9-6-e757.pdf","selector":[{"type":"TextPositionSelector","start":51,"end":64},{"type":"TextQuoteSelector","exact":"Panobinostat ","prefix":" Phase Ib Dose-finding Study of ","suffix":"and Ruxolitinib in Myelofibrosis"}]}]}
>```
>%%
>*%%PREFIX%%Phase Ib Dose-finding Study of%%HIGHLIGHT%% ==Panobinostat== %%POSTFIX%%and Ruxolitinib in Myelofibrosis*
>%%LINK%%[[#^etanbxa6kkl|show annotation]]
>%%COMMENT%%
>帕比司他（panobinostat）是强有力的脱乙酰酶抑制剂，脱乙酰酶是多发性骨髓瘤畸变的目标..
>%%TAGS%%
>
^etanbxa6kkl


>%%
>```annotation-json
>{"created":"2022-08-30T03:47:17.742Z","updated":"2022-08-30T03:47:17.742Z","document":{"title":"hs9-6-e757.pdf","link":[{"href":"urn:x-pdf:b92cff942e6c35408e1de9da383cc941"},{"href":"vault:/hematology-theroy/papers/20220808/hs9-6-e757.pdf"}],"documentFingerprint":"b92cff942e6c35408e1de9da383cc941"},"uri":"vault:/hematology-theroy/papers/20220808/hs9-6-e757.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/hs9-6-e757.pdf","selector":[{"type":"TextPositionSelector","start":923,"end":1160},{"type":"TextQuoteSelector","exact":" impaired JAK signaling and effectively  reduced  splenomegaly  and  improved  BMF  in  phase  1/2 studies.4  The ruxolitinib/panobinostat combination has demonstrated synergistic activity in preclinical MF models5 and a  clinical  study","prefix":"e  deacetylase (HDAC) inhibitor,","suffix":".6  Results  of  the  dose  esca"}]}]}
>```
>%%
>*%%PREFIX%%e  deacetylase (HDAC) inhibitor,%%HIGHLIGHT%% ==impaired JAK signaling and effectively  reduced  splenomegaly  and  improved  BMF  in  phase  1/2 studies.4  The ruxolitinib/panobinostat combination has demonstrated synergistic activity in preclinical MF models5 and a  clinical  study== %%POSTFIX%%.6  Results  of  the  dose  esca*
>%%LINK%%[[#^8rrs0upw2xi|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^8rrs0upw2xi
